MediciNova (NASDAQ:MNOV) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of MediciNova (NASDAQ:MNOV) in a research note issued to investors on Wednesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

MediciNova Price Performance

MNOV stock opened at $2.10 on Wednesday. The business’s 50-day moving average is $1.34 and its two-hundred day moving average is $1.37. The firm has a market capitalization of $103.00 million, a P/E ratio of -11.71 and a beta of 0.72. MediciNova has a 1 year low of $1.12 and a 1 year high of $2.38.

MediciNova Company Profile

MediciNova, Inc, a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. It is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological and other disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID.